April 2nd 2024
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lifileucel Continues to Show Durable Responses in Advanced Melanoma
June 6th 2021With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy
Nivolumab Monotherapy, With Ipilimumab Continuously Improves Outcomes in Advanced Melanoma
June 6th 2021Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.
Adding Lifileucel to Pembrolizumab for Immunotherapy-Naïve Melanoma Improved Responses
June 6th 2021A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting.
Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma
April 11th 2021Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.
Adjuvant Nivolumab Plus Ipilimumab Combo For Late-Stage Melanoma Did Not Meet RFS End Point
April 11th 2021The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.
Adjuvant Immunotherapy Produced Survival Benefit for Patients With High-Risk Stage II Melanoma
March 23rd 2021Adjuvant immunotherapy treatment was associated with a significant survival benefit for patients with stage II melanoma in a study presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care.
Study Identifies Shift in Incidence of Second Primary Cancers in Patients with Metastatic Melanoma
January 27th 2021During the age of systemic immunotherapy, investigators observed a change in the incidence of second primary cancers after metastatic melanoma that included solid tumor and hematologic malignancies.
FDA Grants Orphan Drug Designation to PVSRIPO for Treatment of Advanced Melanoma
January 22nd 2021The novel viral immunotherapy PVSRIPO is designed to stimulate a patient’s innate and adaptive immune system to promote an antitumor response and establish long-term immunologic memory to help keep their cancer at bay.
Phase 3 IMCgp100-202 Trial of Tebentafusp Shows Promise for Metastatic Uveal Melanoma
November 23rd 2020The clinical trial of tebentafusp (IMCgp100) versus investigator’s choice in metastatic uveal melanoma met its pre-defined boundaries for statistical significance of the primary end point of overall survival in its first pre-planned interim analysis.
ctDNA May Be Reliable Predictor of Outcomes with First-Line Immunotherapy for Melanoma
October 19th 2020Pretreatment circulating tumor DNA was found to be a reliable indicator of patient outcome for those with metastatic melanoma in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line setting.
Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning Labels
October 5th 2020A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.